Founded in 1997, Scancell Plc is in the biopharmaceutical industry working on developing and discovering antibodies of monoclonal nature and relevant vaccines for cancer treatment. With its headquarters in Oxford, United Kingdom the company’s shares trade on the London Stock Exchange.
Cancer naturally occurs when numerous fast-growing cancer cells cannot be contained and controlled by the body’s natural defense system. In the process of the growth spurt, they overtake the body’s natural system and develop into tumors. To counter this, Scancell develops immunotherapies that play the role of stimulating the body’s immune system to enable it to fight or prevent cancer. These are AvidiMab, an antibody, which is an anti-glycan and vaccines (Moditope and ImmunoBody). All of which are technologies developed for the attack and destruction of cancer cells. They do this by stimulating the immune system of the patient to actively respond to the developing tumor by rejecting it or destroying it altogether.